Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study

BACKGROUND: Although patients with type 2 diabetes mellitus (T2DM) may fail to achieve adequate hemoglobin A1c (HbA1c) control despite metformin-sulfonylurea (Met-SU) dual therapy, a third-line glucose-lowering medication—including dipeptidyl peptidase-4 inhibitor (DPP4i), insulin, or thiazolidinedi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Carlos K. H., Man, Kenneth K. C., Shi, Margaret, Chan, Esther W., Ho, Chu Wa, Tse, Emily T. Y., Wong, Ian C. K., Lam, Cindy L. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6932752/
https://www.ncbi.nlm.nih.gov/pubmed/31877127
http://dx.doi.org/10.1371/journal.pmed.1002999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6932752/
https://www.ncbi.nlm.nih.gov/pubmed/31877127
http://dx.doi.org/10.1371/journal.pmed.1002999

Ejemplares similares